Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations
The present study describes a patient aged 70 with very high-risk AML who successfully received a nonmyeloablative matched unrelated donor allograft shortly following SARS-CoV-2 infection, which manifested with mild cough, interstitial abnormalities on chest CT, and pancytopenia with profound bone m...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2021/8843063 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556890142277632 |
|---|---|
| author | Maria Kaparou Zbigniew Rudzki Hannah Giles Vidhya Murthy Swathy Srinath Rebecca Lloyd Maria Zahid Ahmed Beena Salhan Saleena Chauhan Bhuvan Kishore Richard Lovell Claire Horgan Shankara Paneesha Evgenia Xenou Anand Lokare Joanne Ewing Hansini Dassanayake Emmanouil Nikolousis Alexandros Kanellopoulos |
| author_facet | Maria Kaparou Zbigniew Rudzki Hannah Giles Vidhya Murthy Swathy Srinath Rebecca Lloyd Maria Zahid Ahmed Beena Salhan Saleena Chauhan Bhuvan Kishore Richard Lovell Claire Horgan Shankara Paneesha Evgenia Xenou Anand Lokare Joanne Ewing Hansini Dassanayake Emmanouil Nikolousis Alexandros Kanellopoulos |
| author_sort | Maria Kaparou |
| collection | DOAJ |
| description | The present study describes a patient aged 70 with very high-risk AML who successfully received a nonmyeloablative matched unrelated donor allograft shortly following SARS-CoV-2 infection, which manifested with mild cough, interstitial abnormalities on chest CT, and pancytopenia with profound bone marrow biopsy histological alterations. In parallel, our study provides bone marrow biopsy data in a series of contemporary patients with serious haematological diseases who had a bone marrow biopsy performed within two weeks of PCR confirmation of SARS-CoV-2 infection. This study is notable because there are no published data describing the bone marrow biopsy changes observed in patients with haematological malignancies and SARS-CoV-2 infection. Finally, it is suggested that nonmyeloablative hematopoietic stem cell transplantation for very high-risk haematological malignancies can be successfully performed following recovery from SARS-CoV-2 infection. |
| format | Article |
| id | doaj-art-5ab799f13c5146aa917806a9c2cda95a |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-5ab799f13c5146aa917806a9c2cda95a2025-02-03T05:44:12ZengWileyCase Reports in Hematology2090-65602090-65792021-01-01202110.1155/2021/88430638843063Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy AlterationsMaria Kaparou0Zbigniew Rudzki1Hannah Giles2Vidhya Murthy3Swathy Srinath4Rebecca Lloyd5Maria Zahid Ahmed6Beena Salhan7Saleena Chauhan8Bhuvan Kishore9Richard Lovell10Claire Horgan11Shankara Paneesha12Evgenia Xenou13Anand Lokare14Joanne Ewing15Hansini Dassanayake16Emmanouil Nikolousis17Alexandros Kanellopoulos18University Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKUniversity Hospitals Birmingham NHS Foundation Trust, London, UKThe present study describes a patient aged 70 with very high-risk AML who successfully received a nonmyeloablative matched unrelated donor allograft shortly following SARS-CoV-2 infection, which manifested with mild cough, interstitial abnormalities on chest CT, and pancytopenia with profound bone marrow biopsy histological alterations. In parallel, our study provides bone marrow biopsy data in a series of contemporary patients with serious haematological diseases who had a bone marrow biopsy performed within two weeks of PCR confirmation of SARS-CoV-2 infection. This study is notable because there are no published data describing the bone marrow biopsy changes observed in patients with haematological malignancies and SARS-CoV-2 infection. Finally, it is suggested that nonmyeloablative hematopoietic stem cell transplantation for very high-risk haematological malignancies can be successfully performed following recovery from SARS-CoV-2 infection.http://dx.doi.org/10.1155/2021/8843063 |
| spellingShingle | Maria Kaparou Zbigniew Rudzki Hannah Giles Vidhya Murthy Swathy Srinath Rebecca Lloyd Maria Zahid Ahmed Beena Salhan Saleena Chauhan Bhuvan Kishore Richard Lovell Claire Horgan Shankara Paneesha Evgenia Xenou Anand Lokare Joanne Ewing Hansini Dassanayake Emmanouil Nikolousis Alexandros Kanellopoulos Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations Case Reports in Hematology |
| title | Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations |
| title_full | Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations |
| title_fullStr | Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations |
| title_full_unstemmed | Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations |
| title_short | Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations |
| title_sort | management of allogeneic stem cell transplantation for high risk aml following sars cov 2 associated pancytopenia with marked bone marrow biopsy alterations |
| url | http://dx.doi.org/10.1155/2021/8843063 |
| work_keys_str_mv | AT mariakaparou managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT zbigniewrudzki managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT hannahgiles managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT vidhyamurthy managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT swathysrinath managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT rebeccalloyd managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT mariazahidahmed managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT beenasalhan managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT saleenachauhan managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT bhuvankishore managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT richardlovell managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT clairehorgan managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT shankarapaneesha managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT evgeniaxenou managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT anandlokare managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT joanneewing managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT hansinidassanayake managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT emmanouilnikolousis managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations AT alexandroskanellopoulos managementofallogeneicstemcelltransplantationforhighriskamlfollowingsarscov2associatedpancytopeniawithmarkedbonemarrowbiopsyalterations |